NeurAxon

About NeurAxon

NeurAxon Pharma operates as a clinical-stage biopharmaceutical company focused on developing therapeutics for pain management. The firm was established in 2004, originating as a spin-out from MCR Research Inc., a medicinal chemistry company based in Toronto. The founder, Dr. Suman Rakhit, who served as the Chief Scientific Officer, brought extensive experience from his previous role as Founder & CEO of MCR Research and holds a Ph.D. in pharmaceutical chemistry.

The company's core strategy centers on the discovery and development of small molecules that inhibit the neuronal nitric oxide synthase (nNOS) enzyme. This enzyme plays a role in modulating pain and central nervous system neuronal sensitization. NeurAxon aims to commercialize these novel molecules that interact with established molecular targets involved in pain management. The company has secured significant funding, raising a total of $55.7 million across nine funding rounds from investors including Orbimed, Ventures West, and Delphi Ventures. The most recent funding was a Series B round in January 2015.

NeurAxon's product pipeline has included several candidates targeting neuropathies. Its lead candidate, NXN-188, was developed as a dual-action small molecule for the treatment of acute migraine and advanced to Phase 2 and 3 trials. Another product, NXN-462, entered Phase 2 trials for addressing chronic migraine and neuropathic pain. The company's business model is rooted in the research and development of these oral products with the potential for future commercialization, addressing a market that includes acute migraine, neuropathic pain, and inflammatory pain.